The Approach to Massive Pulmonary Embolism

ABSTRACT

Massive pulmonary embolism (PE) is surprisingly common and is not necessarily heralded by dramatic symptoms or signs. The death rate from PE remains high, and the most common cause of mortality is recurrent PE, not cancer. Prevention of recurrent embolism with intensive anticoagulation remains the foundation of therapy. The Food and Drug Administration has approved use of the low molecular weight heparin enoxaparin for inpatient treatment of deep venous thrombosis (DVT) with or without PE as a ``bridge'' to warfarin. However, in patients with massive PE, anticoagulation alone often does not suffice to prevent death or disability from chronic pulmonary hypertension. Impending hemodynamic instability due to massive PE and its attendant ominous prognosis can be detected by rapid identification of moderate or severe right ventricular failure (usually easily with transthoracic echocardiography). Successful treatment of overt cardiogenic shock, manifested by systemic arterial hypotension and tachycardia, is far more difficult than implementing a strategy that champions early intervention after the onset of right ventricular failure. Among patients with massive PE, thrombolysis and embolectomy (often performed in the interventional angiography laboratory) are being used with increasing skill and improved outcomes. Intensive pharmacologic therapy and mechanical support devices portend a new era of improved intensive and multidisciplinary management of these gravely ill patients.

KEYWORD

Pulmonary embolism - thrombolysis - embolectomy - heparin - low molecular weight heparin

REFERENCES

• 1 Goldhaber S Z, Visani L, De Rosa M, for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).  Lancet . 1999;  353 1386-1389
• 2 Wolfe M W, Lee R T, Feldstein M L. Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism.  Am Heart J . 1994;  127 1371-1375
• 3 Heit J A, Silverstein M D, Mohr D N. Predictors of survival after deep vein thrombosis and pulmonary embolism. A population-based, cohort study.  Arch Intern Med . 1999;  159 445-453
• 4 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials.  Ann Intern Med . 1999;  130 800-809
• 5 Gould M K, Dembitzer A D, Sanders G D, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effectiveness analysis.  Ann Intern Med . 1999;  130 789-799
• 6 Goldhaber S Z. Optimizing anticoagulant therapy in the management of pulmonary embolism.  Semin Thromb Hemost . 1999;  25 129-133
• 7 Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M de L. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial.  J Thromb Thrombol . 1995;  2 227-229
• 8 The Urokinase Pulmonary Embolism Trial. A national cooperative study.  Circulation . 1973;  47 II-1-108
• 9 Urokinase-Streptokinase Embolism Trial. Phase 2 results. A cooperative study.  JAMA . 1974;  229 1606-1613
• 10 Goldhaber S Z, Haire W D, Feldstein M L. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right ventricular function and pulmonary perfusion.  Lancet . 1993;  341 507-511
• 11 Nass N, McConnell M V, Goldhaber S Z, Chyu S, Solomon S D. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism.  Am J Cardiol . 1999;  83 804-806
• 12 Daniels L B, Parker J A, Patel S R, Grodstein F, Goldhaber S Z. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism.  Am J Cardiol . 1997;  80 184-188
• 13 Kanter D S, Mikkola K M, Patel S R, Parker J A, Goldhaber S Z. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors.  Chest . 1997;  111 1241-1245
• 14 Mikkola K M, Patel S R, Parker J A, Grodstein F, Goldhaber S Z. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis.  Am Heart J . 1997;  134 69-72
• 15 Tebbe U, Graf A, Kamke W. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.  Am Heart J . 1999;  138 39-44
• 16 Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.  N Engl J Med . 1998;  338 409-415
• 17 Greenfield L J, Proctor M C, Williams D M. Long-term experience with transvenous catheter pulmonary embolectomy.  J Vasc Surg . 1993;  18 450-458
• 18 Goldhaber S Z. Integration of catheter thrombectomy into our armamentarium to treat acute pulmonary embolism.  Chest . 1998;  114 1237-1238
• 19 Brady A JB, Crake T, Oakely C M. Percutaneous catheter fragmentation and distal dispersion of a proximal pulmonary embolus.  Lancet . 1991;  338 1186-1189
• 20 Sharafuddin M JA, Hicks M E. Current status of percutaneous mechanical thrombectomy: II. Devices and mechanisms of action.  J Vasc Intervent Radiol . 1998;  9 15-31
• 21 Koning R, Cribier A, Gerber L. A new treatment for severe pulmonary embolism. Percutaneous rheolytic thrombectomy.  Circulation . 1997;  96 2498-2500
• 22 Schmitz-Rode T, Janssens U, Schild H H. Fragmentation of massive pulmonary embolism using a pigtail rotation catheter.  Chest . 1998;  114 1427-1436
• 23 Fava M, Loyola S, Flores P. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism.  J Vasc Intervent Radiol . 1997;  8 261-266
• 24 Brodmann M, Stark G, Pabst E. Pulmonary embolism and intracardiac thrombi-individual therapeutic procedures.  Vasc Med . 2000;  5 27-31
• 25 Meyer G, Tamisier D, Sors H. Pulmonary embolectomy: a 20-year experience at one center.  Ann Thorac Surg . 1991;  51 232-236
• 26 Gulba D C, Schmid C, Borst H G. Medical compared with surgical treatment for massive pulmonary embolism.  Lancet . 1994;  343 576-577
• 27 Stulz P, Schläpfer R, Feer R. Decision making in the surgical treatment of massive pulmonary embolism.  Eur J Cardiothorac Surg . 1994;  8 188-193
• 28 Ullmann M, Hemmer W, Hannekum A. The urgent pulmonary embolectomy: mechanical resuscitation in the operating theatre determines the outcome.  Thorac Cardiovasc Surg . 1999;  47 5-8
• 29 Archibald C J, Auger W R, Fedullo P F. Long-term outcome after pulmonary thromboendarterectomy.  Am J Respir Crit Care Med . 1999;  160 523-528
• 30 Layish D T, Tapson V F. Pharmacologic hemodynamic support in massive pulmonary embolism.  Chest . 1997;  111 218-224